ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,460.48
-0.41%
Dow Jones
39,118.86
-0.12%
US Dollar vs MXN
18.3385
0.00%
Brent Oil
84.85
0.00%
Bitcoin
60,982.79
1.11%
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Canadá
  5. CSE
  6. Revive Therapeutics Ltd (RVV)

  7. Revive Therapeutics Ltd (RVV) Noticias

RVV

Revive Therapeutics (RVV)

Revive Therapeutics Ltd
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:CSE:RVV
FechaHoraFuenteTítuloSímboloCompañía
18/04/202209:26InvestorsHub NewsWireRevive Therapeutics Announces Publication of Research Data with Bucillamine in COVID-19CSE:RVVRevive Therapeutics Ltd
12/04/202207:00InvestorsHub NewsWireRevive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19CSE:RVVRevive Therapeutics Ltd
17/01/202208:13InvestorsHub NewsWireRevive Therapeutics Provides Update of Psilocybin Pharmaceutical ProgramsCSE:RVVRevive Therapeutics Ltd
07/01/202207:05InvestorsHub NewsWireRevive Therapeutics Clarifies Status of Its Phase 3 Clinical Trial for Bucillamine in COVID-19CSE:RVVRevive Therapeutics Ltd
18/08/202105:00InvestorsHub NewsWireRevive Therapeutics Signs Exclusive Worldwide License Agreement For Medicinal Mushroom Ganoderma Lucidum To Treat CancerCSE:RVVRevive Therapeutics Ltd
12/08/202108:56InvestorsHub NewsWireRevive Confirms No Material Undisclosed InformationCSE:RVVRevive Therapeutics Ltd
10/08/202107:52InvestorsHub NewsWireRevive Therapeutics Provides Update on Psychedelics Clinical Product PipelineCSE:RVVRevive Therapeutics Ltd
28/06/202107:00InvestorsHub NewsWireRevive Therapeutics Approved to Trade on the OTCQB MarketCSE:RVVRevive Therapeutics Ltd
08/06/202108:12InvestorsHub NewsWireRevive Therapeutics Partners with Supriya to Pursue EUA for Bucillamine to Treat COVID in IndiaCSE:RVVRevive Therapeutics Ltd
17/05/202108:48InvestorsHub NewsWireRevive Therapeutics Enters into Feasibility Agreement with LTS Lohmann to Develop Oral Psilocybin Thin Film StripCSE:RVVRevive Therapeutics Ltd
03/05/202108:32InvestorsHub NewsWireRevive Therapeutics Enters Into Research Agreement with UCSF For Bucillamine As Potential Treatment For Severe COVID-19CSE:RVVRevive Therapeutics Ltd
22/04/202107:26InvestorsHub NewsWireRevive Therapeutics Announces Successful Research Results for Oral Thin Film Psilocybin and Filing of U.S. Provisional ....contCSE:RVVRevive Therapeutics Ltd
24/03/202108:15InvestorsHub NewsWireRevive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19CSE:RVVRevive Therapeutics Ltd
11/02/202107:05InvestorsHub NewsWireRevive Therapeutics Provides Update on Cannabinoid Pharmaceuticals ProgramCSE:RVVRevive Therapeutics Ltd
27/01/202107:13InvestorsHub NewsWireRevive Therapeutics in Phase 3 clinical trial for COVID-19 treatmentCSE:RVVRevive Therapeutics Ltd
18/01/202108:51InvestorsHub NewsWireHow Combat Sports Are Researching Micro-Dosing Psychedelics To Treat Brain InjuriesCSE:RVVRevive Therapeutics Ltd
31/12/202007:30InvestorsHub NewsWireDr. John Fahy Joins Revive Therapeutics as Scientific and Clinical Advisor for COVID-19 FDA Phase 3 StudyCSE:RVVRevive Therapeutics Ltd
22/12/202010:05InvestorsHub NewsWireRevive Therapeutics Announces LOI to Acquire PharmaTher's Psilocybin ProgramCSE:RVVRevive Therapeutics Ltd
31/07/202008:46InvestorsHub NewsWireRevive Therapeutics Announces U.S. FDA Approval of Confirmatory Phase 3 Clinical Trial for Bucillamine in COVID-19CSE:RVVRevive Therapeutics Ltd
23/04/202008:47InvestorsHub NewsWireRevive Therapeutics Announces U.S. FDA Recommendation to Proceed Directly Into A Phase 3 Confirmatory Clinical TrialCSE:RVVRevive Therapeutics Ltd
 Showing the most relevant articles for your search:CSE:RVV

Su Consulta Reciente

USOTC
BNPQY
BNP Paribas (QX)
SPI
SP500
S&P 500
USOTC
ADDYY
Adidas (QX)
NYSE
BAC
Bank of America
PM
XAUUSD
Gold vs US Dollar
NYSE
CVX
Chevron
NYSE
KO
Coca Cola
AMEX
XLF
Financial Select Sector
FX
EURMXN
Euro vs MXN
NYSE
AXP
American Express
AMEX
XLV
Health Care Select Sector
USI
USTECH100
US Tech 100
CCOM
US30
US 30
COIN
ETHUSD
Ethereum
FX
USDMXN
US Dollar vs MXN
AMEX
XLE
Energy Select Sector SPDR
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados